OBJECTIVES: Chitinase 3-like 1 (CHI3L1) is an extracellular monomeric single-chain glycoprotein expressed by many types of cells. Its elevated levels were found in cerebrospinal fluid in central nervous system (CNS) inflammatory diseases patients. The aim of the study was 1) to validate the reference interval of cerebrospinal fluid (CSF) CHI3L1 in a control group; 2) to measure the CHI3L1 concentration in different diagnosis groups .including multiple sclerosis (MS); and 3) to correlate those values with other biomarkers of axonal damage or neuroinflammation in different grous. METHODS: The study included 132 CSF samples sent to the Department of Clinical Biochemistry, Institute of Laboratory Diagnostics, University Hospital Ostrava. Concentrations of CHI3L1, CXCL13 chemokine, neurofilament light chains, and phosphorylated neurofilament heavy chains were determined by enzyme-linked immunosorbent assays. IgG oligoclonal bands were detected by isoelectric focusing in agarose gels followed by immunofixation. IgM and FLC oligoclonal bands were analyzed by IEF followed by affinity immunoblotting. The group consisted of 42 patients with multiple sclerosis, 14 with clinically isolated syndrome, 11 with other central nervous system inflammatory diseases, 46 with non-inflammatory diseases of the central nervous system, 4 with inflammatory diseases of the peripheral nervous system, and 15 controls. RESULTS: The estimated reference values of CHI3L1 were 28.6-182.5 μg.L-1. Statistically significant differences of CSF CHI3L1 concentrations were found among diagnosis groups (p < 0.0001), after age adjustment (p = 0.002). There was a statistically significant relationship between CHI3L1 and NFL in the MS group (rs = 0.460; P = 0.002), and between CHI3L1 and pNFH in the MS group (rs = 0.691; P < 0.001). No statistically significant difference was found in the categorical comparison of CHI3L1 in the MS group and other diagnostic groups as well as when using the Mann-Whitney U test for CHI3L1 with additional parameters with and without oligoclonal bands present. CONCLUSIONS: CSF CHI3L1 values differ depending on diagnosis and correlate significantly with concentrations of the axonal damage markers CSF neurofilament light chains, and CSF phosphorylated neurofilament heavy chains, but not with CSF concentrations of the inflammatory marker CXCL13. Thus, CSF CHI3L1 could be another promising prognostic, albeit probably etiologically nonspecific, biomarker of MS.

Clinic of Neurology University Hospital Ostrava Ostrava Czech Republic

Department of Clinical Biochemistry Institute of Laboratory Diagnostics University Hospital Ostrava Ostrava Czech Republic

Zobrazit více v PubMed

Tintore M, Rovira Á, Río J, Otero-Romero S, Arrambide G, Tur C, et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. 10.1093/brain/awv105 . PubMed DOI

Sellebjerg F, Royen L, Soelberg Sørensen P, Oturai AB, Jensen PEH. Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis. Mult Scler. 2019; 25(11):1444–1451. 10.1177/1352458518794308 . PubMed DOI

Khademi M, Kockum I, Andersson ML, Iacobaeus E, Brundin L, Sellebjerg F, et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler. 2011;17(3):335–343. 10.1177/1352458510389102 . PubMed DOI

Llorens F, Thüne K, Tahir W, Kanata E, Diaz-Lucena D, Xanthopoulos K, et al. YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias. Mol Neurodegener. 2017. November 10;12(1):83 10.1186/s13024-017-0226-4 . PubMed DOI PMC

Lee CG, Da Silva CA, Dela Cruz CS, Ahangari F, Ma B, Kang M-J, et al. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling and injury. Annu Rev Physiol. 2011;73,479–501. 10.1146/annurev-physiol-012110-142250 . PubMed DOI PMC

Canto E, Tintore M, Villar LM, Costa C, Nurtdinov R, Alvarez-Cermeno JC, et al. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain. 2015;138,918–31. 10.1093/brain/awv017 . PubMed DOI

Bonneh-Barkay D, Bissel SJ, Wang G, Fish KN, Nicholl GC, Darko SW, et al. YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor. Am J Pathol 2008,173:130–143. 10.2353/ajpath.2008.080045 . PubMed DOI PMC

Burman J, Raininko R, Blennow K, Zetterberg H, Axelsson M, Malmeström C. YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis. J. Neuroinflammation 2016;292:52–57. 10.1016/j.jneuroim.2016.01.013 . PubMed DOI

Bonneh-Barkay D, Wang G, Starkey A, Hamilton RL, Wiley CA. In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J. Neuroinflammation. 2010;7,34 10.1186/1742-2094-7-34 . PubMed DOI PMC

Clinical and Laboratory Standards Institute (CLSI). Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guideline CLSI document C28–A3. 3rd edWayne: PA: Clinical and Laboratory Standards Institute; 2008.

Pavlov IY, Wilson AR, Delgado JC. Resampling approach for determination of the method for reference interval calculation in clinical laboratory practice. Clin Vaccine Imunol 2010;17;1217–22. 10.1128/CVI.00112-10 . PubMed DOI PMC

Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–173. 10.1016/S1474-4422(17)30470-2 PubMed DOI

Sindic CJM, Laterre EC. Oligoclonal free kappa and lambda bands in the cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases. An immunoaffinity-mediated capillary blot study. J Neuroimmunol 1991;33:63–72. 10.1016/0165-5728(91)90035-6 . PubMed DOI

Zeman D, Hradílek P, Švagera Z, Mojžíšková E, Woznicová I, Zapletalová O. Detection of oligoclonal IgG kappa and IgG lambda using Hevylite antibodies. Comparison with oligoclonal free light chain pattern. Fluids Barriers CNS 2012;9:5 10.1186/2045-8118-9-5 . PubMed DOI PMC

Zeman D, Hradilek P, Kusnierova P, Piza R, Reguliova K, Woznicova I, et al. Oligoclonal free light chains in cerebrospinal fluid as markers of intrathecal inflammation. Comparison with oligoclonal IgG. Biomed Pap Med Fac Univ Palackz Olomouc Cyech Repub. 2015;159(1):104–113. 10.5507/bp.2014.058 . PubMed DOI

McHugh ML. Interrater reliability: the kappa statistic. Biochemia Medica 2012;22(3):276–282. . PubMed PMC

Stata Version 13, Stata Press Publication, Texas, 2013. ISBN-13:978-1-59718-129-7.

Arrambide G., Espejo C., Eixarch H., Villar LM., Alvarez-Cermeño JC, Picon C, et al. Neurofilament light chain level is a weak risk factor for the development of MS. Neurology 2016;87(11):1076–1084. 10.1212/WNL.0000000000003085 PubMed DOI PMC

Neurofilament (pNf-H) ELISA, Euroimmun Medizinische Labordiagnostika AG (Germany). Version: 20/07/2017.

CXCL13 ELISA, Euroimmun Medizinische Labordiagnostika AG (Germany). Version: 16/6/2018.

Modvig S, Degn M, Roed H, Sørensen TL, Larsson HBW, Langkilde AR, et al. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis. Mult Scler 2015;21(14),1761–1770. 10.1177/1352458515574148 . PubMed DOI

Baldacci F, Lista S, Palermo G, Giorgi FS, Vergallo A, Hampel H. The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/31195846" \o "Expert review of proteomics." Expert Rev Proteomics. 2019; 16(7),593–600. 10.1080/14789450.2019.1628643 . PubMed DOI

Krumbholz M, Theil D, Cepok S, Hemmer B, Kivisäkk P, Ransohoff RM, et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 2006;129:200–211. 10.1093/brain/awh680 . PubMed DOI

Khademi M, Kockum I, Andersson ML, Iacobaeus E, Brundin L, Sellebjerg F, et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler 2011;17(3):335–343. 10.1177/1352458510389102 . PubMed DOI

Senel M, Tumani H, Lauda F, Presslauer S, Mojib-Yezdani R, Otto M, et al. Cerebrospinal Fluid Immunoglobulin Kappa Light Chain in Clinically Isolated Syndrome and Multiple Sclerosis. Plos One. 2014. April 2;9(4):e88680 10.1371/journal.pone.0088680 . PubMed DOI PMC

Sindic CJ, Van Antwerpen MP, Goffette S. The intrathecal humoral immune response: laboratory analysis and clinical relevance. Clin Chem Lab Med 2001;39:333–40. 10.1515/CCLM.2001.052 . PubMed DOI

Link H, Huang YM. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: An update on methodology and clinical usefulness. J Neuroimmunol 2006;180:17–28. 10.1016/j.jneuroim.2006.07.006 . PubMed DOI

Chitinase-3-Like 1 Protein (CHI3L1) Levels in Patients With Cognitive Deficits and Movement Disorders: Comparison With Other Biomarkers